Anti-sclerostin antibodies: Utility in treatment of osteoporosis

Maturitas

Volumn 78, Issue 3, 2014, Pages 199-204

  Clarke, Bart L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti sclerostin antibody; Blosozumab; Osteoporosis; Romosozumab; Sclerostin; Treatment

Indexed keywords

BLOSOZUMAB; ROMOSOZUMAB; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, HUMAN;

BONE DENSITY; BONE MASS; CLINICAL STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FRACTURE HEALING; METAPHYSIS; NONHUMAN; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; BONE DEVELOPMENT; DRUG EFFECTS; GENETIC MARKER; HUMAN; IMMUNOLOGY; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84902687057     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.04.016     Document Type: Review

References (25)

1. T.D. Rachner, S. Khosla, and L.C. Hofbauer Osteoporosis: now and the future Lancet 377 9773 2011 1276 1287
2. E. Canalis Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches Nat Rev Endocrinol 9 2013 575 583
3. E.M. Lewiecki New targets for intervention in the treatment of postmenopausal osteoporosis Nat Rev Rheumatol 7 2011 631 638
4. A.G. Costa, J.P. Bilezikian, and E.M. Lewiecki Update on romosozumab: a humanized monoclonal antibody to sclerostin Expert Opin Biol Ther 14 2014 697 707
5. H.Z. Ke, W.G. Richards, X. Li, and M.S. Ominsky Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases Endocr Rev 33 2012 747 783
6. M.R. McClung, A. Grauer, and S. Boonen et al. Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 370 2014 412 420
7. C.B. Becker Sclerostin inhibition for osteoporosis - a new approach N Engl J Med 370 2014 476 477
8. F. Cosman, E.F. Eriksen, and C. Recknor et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J Bone Miner Res 26 2011 503 511
9. J.N. Tsai, A.V. Uihlein, and H. Lee et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial Lancet 382 2013 50 56
10. D. Padhi, M. Allison, and A.J. Kivitz et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study J Clin Pharmacol 2013 [Epub ahead of print, November 23]
11. D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 26 2011 19 26
12. M. van Dinther, J. Zhang, and S.E. Weidauer et al. Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signaling PLoS ONE 8 2013 e62295
13. X. Li, M.S. Ominsky, and K.S. Warmington et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 2009 578 588
14. X. Li, K.S. Warmington, and Q.T. Niu et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats J Bone Miner Res 25 2010 2647 2656
15. M.S. Ominsky, F. Vlasseros, and J. Jolette et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength J Bone Miner Res 25 2010 948 959
16. R.D. Ross, L.H. Edwards, and A.S. Acerbo et al. Bone matrix quality following sclerostin antibody treatment J Bone Miner Res 2014 [Epub ahead of print, January 28]
17. F. Agholme, H. Isaksson, X. Li, H.Z. Ke, and P. Aspenberg Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats Acta Orthop 82 2011 628 632
18. F. Alaee, M.S. Virk, and H. Tang et al. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model J Orthop Res 32 2014 197 203
19. M.S. Virk, F. Alaee, H. Tang, M.S. Ominsky, H.Z. Ke, and J.R. Lieberman Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model J Bone Joint Surg Am 95 2013 694 701
20. L. Cui, H. Cheng, and C. Song et al. Time-dependent effects of sclerostin antibody on a mouse fracture healing model J Musculoskelet Neuronal Interact 13 2013 178 184
21. M.S. Ominsky, C. Li, and X. Li et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones J Bone Miner Res 26 2011 1012 1021
22. C. Hamann, M. Rauner, and Y. Höhna et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus J Bone Miner Res 28 2013 627 638
23. B.P. Sinder, M.M. Eddy, M.S. Ominsky, M.S. Caird, J.C. Marini, and K.M. Kozloff Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta J Bone Miner Res 28 2013 73 80
24. X. Li, M.S. Ominsky, and K.S. Warmington et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats Endocrinology 152 2011 3312 3322
25. J. McColm, L. Hu, T. Womack, C.C. Tang, and A.Y. Chiang Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women J Bone Miner Res 29 2014 935 943